{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T01:59:40Z","timestamp":1775959180936,"version":"3.50.1"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,1]]},"abstract":"<jats:p>Objective. To evaluate viral vaccination immunity and booster responses in children treated successfully for acute lymphoblastic leukemia by chemotherapy and to study the response to treatment of antibody-producing plasma cells that are important for persistence of humoral immunity.<\/jats:p>\n               <jats:p>Methods. Forty-three children who were in continuous first remission for a median of 5 years (range: 2\u201312 years) were studied. Before the leukemia was diagnosed, all children had been immunized against measles, mumps, and rubella according to the Swedish National immunization program. We analyzed levels of serum antibodies against measles and rubella by enzyme immunoassays. Avidity tests for measles antibodies were concomitantly performed by enzyme-linked immunosorbent assay for measles virus immunoglobulin G detection. The proportion of plasma cells in bone marrow was studied by flow cytometry at different times during treatment and follow-up. Children who lacked protective levels of antibodies to vaccination antigens were reimmunized. Serum was collected 3 months after immunization to assess vaccination responses.<\/jats:p>\n               <jats:p>Results. After completion of the treatment, only 26 of the 43 children (60%) were found to be immune against measles and 31 (72%) against rubella. The proportion of bone marrow plasma cells decreased during treatment but returned to normal after 6 months. Revaccination caused both primary and secondary immune responses. Six of the 14 children without immunity failed to achieve protective levels of specific antibodies against measles and 3 against rubella.<\/jats:p>\n               <jats:p>Conclusions. Our finding of loss of antibodies against measles and rubella in children treated with intensive chemotherapy suggests that reimmunization of these patients is necessary after completion of the treatment. To determine reimmunization schedules for children treated with chemotherapy, vaccination responses need to be studied further.<\/jats:p>","DOI":"10.1542\/peds.109.6.e91","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"e91-e91","source":"Crossref","is-referenced-by-count":111,"title":["Current Chemotherapy Protocols for Childhood Acute Lymphoblastic Leukemia Induce Loss of Humoral Immunity to Viral Vaccination Antigens"],"prefix":"10.1542","volume":"109","author":[{"given":"Anna","family":"Nilsson","sequence":"first","affiliation":[{"name":"Pediatric Cancer Research Unit, Astrid Lindgren Children Hospital, Stockholm, Sweden"},{"name":"Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"De Milito","sequence":"additional","affiliation":[{"name":"Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pa\u0308r","family":"Engstro\u0308m","sequence":"additional","affiliation":[{"name":"Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareta","family":"Nordin","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Karolinska Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Grillner","sequence":"additional","affiliation":[{"name":"Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Pediatrics, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Chiodi","sequence":"additional","affiliation":[{"name":"Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Bjo\u0308rk","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Research Unit, Astrid Lindgren Children Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,6,1]]},"reference":[{"key":"2021121006233141800_R1","doi-asserted-by":"crossref","unstructured":"Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection. I. Empiric therapy for fever and neutropenia and preventive strategies. J Pediatr.1991;119:679\u2013694","DOI":"10.1016\/S0022-3476(05)80281-1"},{"key":"2021121006233141800_R2","doi-asserted-by":"crossref","unstructured":"Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin\u2019s lymphoma: a randomized controlled trial. Blood.1992;80:1430\u20131436","DOI":"10.1182\/blood.V80.6.1430.bloodjournal8061430"},{"key":"2021121006233141800_R3","doi-asserted-by":"crossref","unstructured":"Mustafa M, Buchanan G, Winick N, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol.1998;20:451\u2013457","DOI":"10.1097\/00043426-199809000-00008"},{"key":"2021121006233141800_R4","doi-asserted-by":"crossref","unstructured":"De Vaan GAM, Van Munster PJJ, Backeren JAJM. Recovery of immune function after cessation of maintenance therapy in acute lymphoblastic leukemia of childhood. Eur J Pediatr.1982;139:113\u2013117","DOI":"10.1007\/BF00441492"},{"key":"2021121006233141800_R5","doi-asserted-by":"crossref","unstructured":"Alanko S, Pelliniemi T-T, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer.1992;69:1481\u20131486","DOI":"10.1002\/1097-0142(19920315)69:6<1481::AID-CNCR2820690628>3.0.CO;2-L"},{"key":"2021121006233141800_R6","doi-asserted-by":"crossref","unstructured":"Mackall C, Fleisher T, Brown M, et al. Age, thymopoesis and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med.1995;332:143\u2013149","DOI":"10.1056\/NEJM199501193320303"},{"key":"2021121006233141800_R7","doi-asserted-by":"crossref","unstructured":"Armitage R, Goldstone A, Richards JD, Cawley JC. Lymphocyte function after autologous bone marrow transplantation (BMT): a comparison with patients treated with allogeneic BMT and chemotherapy only. Br J Haematol.1986;63:637\u2013647","DOI":"10.1111\/j.1365-2141.1986.tb07547.x"},{"key":"2021121006233141800_R8","doi-asserted-by":"crossref","unstructured":"Azuma E, Nagai M, Qi J, et al. CD4+T-lymphocytopenia in long term survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol.1998;30:40\u201345","DOI":"10.1002\/(SICI)1096-911X(199801)30:1<40::AID-MPO11>3.0.CO;2-C"},{"key":"2021121006233141800_R9","doi-asserted-by":"crossref","unstructured":"Mackall C, Fleisher T, Brown M, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood.1997;89:3700\u20133707","DOI":"10.1182\/blood.V89.10.3700"},{"key":"2021121006233141800_R10","doi-asserted-by":"crossref","unstructured":"Alanko S, Salmi TT, Pelliniemi T-T. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol.1994;11:281\u2013292","DOI":"10.3109\/08880019409141671"},{"key":"2021121006233141800_R11","doi-asserted-by":"crossref","unstructured":"Ogra PL, Sinks LF, Karzon DT. Poliovirus antibody response in patients with acute leukemia. J Pediatr.1971;79:444\u2013449","DOI":"10.1016\/S0022-3476(71)80154-3"},{"key":"2021121006233141800_R12","unstructured":"Ljungman P, Cordonnier C, de Bock R, et al. Immunizations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant.1995;15:455\u2013460"},{"key":"2021121006233141800_R13","unstructured":"Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant.1992;9:427\u2013432"},{"key":"2021121006233141800_R14","doi-asserted-by":"crossref","unstructured":"Waldmann TA, Strober W: Metabolism of immunoglobulins. Prog Allergy.1969;13:1\u2013110","DOI":"10.1159\/000385919"},{"key":"2021121006233141800_R15","doi-asserted-by":"crossref","unstructured":"Gray D, Siepmann K, van Essen D, et al. B-T lymphocyte interactions in the generation and survival of memory cells. Immunol Rev.1996;150:45\u201361","DOI":"10.1111\/j.1600-065X.1996.tb00695.x"},{"key":"2021121006233141800_R16","doi-asserted-by":"crossref","unstructured":"Slifka M, Antia R, Whitmire J, Ahmed R. Humoral immunity due to long lived plasma cells. Immunity.1998;8:363\u2013372","DOI":"10.1016\/S1074-7613(00)80541-5"},{"key":"2021121006233141800_R17","doi-asserted-by":"crossref","unstructured":"Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature.1997;388:133\u2013134","DOI":"10.1038\/40540"},{"key":"2021121006233141800_R18","doi-asserted-by":"crossref","unstructured":"Christenson B, Bo\u0308ttiger M, Heller L. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden. BMJ.1983;287:389\u2013391","DOI":"10.1136\/bmj.287.6389.389"},{"key":"2021121006233141800_R19","doi-asserted-by":"crossref","unstructured":"Gustafsson G, Schmiegelow K, Forestier E, et al. Improving the outcome through two decades in childhood ALL in the Nordic countries: impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia.2000;14:2267\u20132275","DOI":"10.1038\/sj.leu.2401961"},{"key":"2021121006233141800_R20","doi-asserted-by":"crossref","unstructured":"Lee M-S, Cohen B, Hand J, Nokes JD. A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Methods.1999;78:209\u2013217","DOI":"10.1016\/S0166-0934(98)00178-5"},{"key":"2021121006233141800_R21","doi-asserted-by":"crossref","unstructured":"Forghani B, Schmidt NJ. Antigen requirements, sensitivity and specificity of enzyme immunoassays for measles and rubella viral antibodies. J Clin Microbiol.1979;9:657\u2013664","DOI":"10.1128\/jcm.9.6.657-664.1979"},{"key":"2021121006233141800_R22","doi-asserted-by":"crossref","unstructured":"Narita M, Yamada S, Matsuzono Y, Itakura O, Togashi T, Kikuta H. Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Clin Diagn Lab Immunol.1996;3:211\u2013215","DOI":"10.1128\/cdli.3.2.211-215.1996"},{"key":"2021121006233141800_R23","doi-asserted-by":"crossref","unstructured":"Abrahamsson J, Marky I, Mellander L. Immunoglobulin levels and lymphocyte response to mitogenic stimulation in children with malignant disease during treatment and follow up. Acta Paediatr.1995;84:177\u2013182","DOI":"10.1111\/j.1651-2227.1995.tb13605.x"},{"key":"2021121006233141800_R24","doi-asserted-by":"crossref","unstructured":"Van den Does-van den Berg A, Hermans J, Nagel J, van Steenis. Immunity to diphtheria, pertussis, tetanus and poliomyelitis in children with acute lymphoblastic leukemia after cessation of therapy. Pediatrics.1981;67:222\u2013229","DOI":"10.1542\/peds.67.2.222"},{"key":"2021121006233141800_R25","doi-asserted-by":"crossref","unstructured":"Caver TE, Slobod KS, Flynn PM, et al. Profound abnormalities of the B-T ratio during chemotherapy for pediatric acute lymphoblastic leukemia. Leukemia.1998;12:619\u2013622","DOI":"10.1038\/sj.leu.2400970"},{"key":"2021121006233141800_R26","doi-asserted-by":"crossref","unstructured":"Ochsenbein AF, Pinschewer DD, Sierro S, Horvath E, Hengartner H, Zinkernagel RM. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A.2000;97:13263\u201313268","DOI":"10.1073\/pnas.230417497"},{"key":"2021121006233141800_R27","doi-asserted-by":"crossref","unstructured":"Pihlgren M, Schallert N, Tougne C, et al. Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur J Immunol.2001;31:939\u2013946","DOI":"10.1002\/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I"},{"key":"2021121006233141800_R28","doi-asserted-by":"crossref","unstructured":"Broliden K, Leven B, Arneborg M, Bo\u0308ttiger M. Immunity to measles before and after MMR booster or primary vaccination at 12 years of age in the first generation offered the 2-dose immunization programme. Scand J Infect Dis.1998;30:23\u201327","DOI":"10.1080\/003655498750002259"},{"key":"2021121006233141800_R29","doi-asserted-by":"crossref","unstructured":"Christenson B, Bo\u0308ttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine.1994;12:41\u201345","DOI":"10.1016\/0264-410X(94)90009-4"},{"key":"2021121006233141800_R30","unstructured":"King SM, Saunders E, Petric M, Gold R. Response to measles, mumps and rubella vaccine in pediatric bone marrow transplant recipients. Bone Marrow Transplant.1996;17:633\u2013636"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/e91\/996018\/pe0602000e91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/e91\/996018\/pe0602000e91.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:33:17Z","timestamp":1639146797000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/6\/e91\/64154\/Current-Chemotherapy-Protocols-for-Childhood-Acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2002,6,1]]},"published-print":{"date-parts":[[2002,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.6.e91","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,1]]}}}